Prognostic factors for overall survival and safety of trans-arterial chemoembolization (TACE) with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with colorectal liver metastases

1. Dyba T, Randi G, Bray F, Martos C, Giusti F, Nicholson N, et al. The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer 2021; 157: 308–47. doi: 10.1016/j.ejca.2021.07.039 DybaT RandiG BrayF MartosC GiustiF NicholsonN The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers Eur J Cancer 2021 157 308 47 10.1016/j.ejca.2021.07.039 Open DOISearch in Google Scholar

2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–49. doi: 10.3322/caac.21660 SungH FerlayJ SiegelRL LaversanneM SoerjomataramI JemalA Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2021 71 209 49 10.3322/caac.21660 Open DOISearch in Google Scholar

3. Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42: 2212–21. doi: 10.1016/j.ejca.2006.04.012 Van CutsemE NordlingerB AdamR KöhneCH PozzoC PostonG Towards a pan-European consensus on the treatment of patients with colorectal liver metastases Eur J Cancer 2006 42 2212 21 10.1016/j.ejca.2006.04.012 Open DOISearch in Google Scholar

4. Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schalke M, Schlitt HJ. Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer 2014; 14: 810. doi: 10.1186/1471-2407-14-810 HacklC NeumannP GerkenM LossM Klinkhammer-SchalkeM SchlittHJ Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma BMC Cancer 2014 14 810 10.1186/1471-2407-14-810 Open DOISearch in Google Scholar

5. Engstrand J, Nilsson H, Strömberg C, Jonas E, Freedman J. Colorectal cancer liver metastases – a population-based study on incidence, management and survival. BMC Cancer 2018; 18: 78. doi: 10.1186/s12885-017-3925-x EngstrandJ NilssonH StrömbergC JonasE FreedmanJ Colorectal cancer liver metastases – a population-based study on incidence, management and survival BMC Cancer 2018 18 78 10.1186/s12885-017-3925-x Open DOISearch in Google Scholar

6. Brecelj E, Velenik V, Reberšek M, Boc N, Oblak I, Zadnik V, et al. [Recommendations for the diagnosis and treatment of patients with colorectal cancer]. [Slovenian]. Onkologija 2020; 6: 60–92. doi: 10.25670/oi2020-012on BreceljE VelenikV ReberšekM BocN OblakI ZadnikV [Recommendations for the diagnosis and treatment of patients with colorectal cancer]. [Slovenian] Onkologija 2020 6 60 92 10.25670/oi2020-012on Open DOISearch in Google Scholar

7. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 016; 27: 1386–422. doi: 10.1093/annonc/mdw235 Van CutsemE CervantesA AdamR SobreroA Van KriekenJH AderkaD ESMO consensus guidelines for the management of patients with metastatic colorectal cancer Ann Oncol 2016 27 1386 422 10.1093/annonc/mdw235 Open DOISearch in Google Scholar

8. Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 10–32. doi: 10.1016/j.annonc.2022.10.003 CervantesA AdamR RosellóS ArnoldD NormannoN TaïebJ Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up Ann Oncol 2023 34 10 32 10.1016/j.annonc.2022.10.003 Open DOISearch in Google Scholar

9. Fiorentini G, Sarti D, Nani R, Aliberti C, Fiorentini C, Guadagni S. Updates of colorectal cancer liver metastases therapy: review on DEBIRI. Hepatic Oncol 2020; 21;7: HEP16. doi: 10.2217/hep-2019-0010 FiorentiniG SartiD NaniR AlibertiC FiorentiniC GuadagniS Updates of colorectal cancer liver metastases therapy: review on DEBIRI Hepatic Oncol 2020 21 7 HEP16 10.2217/hep-2019-0010 Open DOISearch in Google Scholar

10. Scevola G, Loreni G, Rastelli M, Sposato S, Ramponi S, Miele V. Third-line treatment of colorectal liver metastases using DEBIRI chemoembolisation. Med Oncol 2017; 34: 37. doi: 10.1007/s12032-017-0890-9 ScevolaG LoreniG RastelliM SposatoS RamponiS MieleV Third-line treatment of colorectal liver metastases using DEBIRI chemoembolisation Med Oncol 2017 34 37 10.1007/s12032-017-0890-9 Open DOISearch in Google Scholar

11. Szemitko M, Golubinska-Szemitko E, Sienko J, Falkowski A, Wiernicki I. Efficacy of liver chemoembolization after prior cetuximab monotherapy in patients with metastatic colorectal cancer. Cancers 2023; 15: 541. doi: 10.3390/cancers15020541 SzemitkoM Golubinska-SzemitkoE SienkoJ FalkowskiA WiernickiI Efficacy of liver chemoembolization after prior cetuximab monotherapy in patients with metastatic colorectal cancer Cancers 2023 15 541 10.3390/cancers15020541 Open DOISearch in Google Scholar

12. Fereydooni A, Letzen B, Ghani MA, Miszczuk MA, Huber S, Chapiro J, et al. Irinotecan-eluting 75–150-mum embolics lobar chemoembolization in patients with colorectal cancer liver metastases: a prospective single-center Phase I study. J Vasc Interv Radiol 2018; 29: 1646–53. doi: 10.1016/j.jvir.2018.08.010 FereydooniA LetzenB GhaniMA MiszczukMA HuberS ChapiroJ Irinotecan-eluting 75–150-mum embolics lobar chemoembolization in patients with colorectal cancer liver metastases: a prospective single-center Phase I study J Vasc Interv Radiol 2018 29 1646 53 10.1016/j.jvir.2018.08.010 Open DOISearch in Google Scholar

13. Iezzi R, Marsico VA, Guerra A, Cerchiaro E, Cassano A, Basso M, et al. Transarterial chemoembolization with irinotecan-loaded drug-eluting beads (DEBIRI) and capecitabine in refractory liver prevalent colorectal metastases: a Phase II single-center study. Cardiovasc Intervent Radiol 2015; 6:1523–31. doi: 10.1007/s00270-015-1080-9 IezziR MarsicoVA GuerraA CerchiaroE CassanoA BassoM Transarterial chemoembolization with irinotecan-loaded drug-eluting beads (DEBIRI) and capecitabine in refractory liver prevalent colorectal metastases: a Phase II single-center study Cardiovasc Intervent Radiol 2015 6 1523 31 10.1007/s00270-015-1080-9 Open DOISearch in Google Scholar

14. Martin RCG, Scoggins CR, Schreeder M, Rilling WS, Laing CJ, Tatum CM, et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer 2015; 121: 3649–58. doi: 10.1002/cncr.29534 MartinRCG ScogginsCR SchreederM RillingWS LaingCJ TatumCM Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis Cancer 2015 121 3649 58 10.1002/cncr.29534 Open DOISearch in Google Scholar

15. Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse quality assurance document and standards for classification of complications: the Cirse classification system. Cardiovasc Intervent Radiol 2017; 40: 1141–6. doi: 10.1007/s00270-017-1703-4 FilippiadisDK BinkertC PellerinO HoffmannRT KrajinaA PereiraPL Cirse quality assurance document and standards for classification of complications: the Cirse classification system Cardiovasc Intervent Radiol 2017 40 1141 6 10.1007/s00270-017-1703-4 Open DOISearch in Google Scholar

16. Ocvirk J, Moltara ME, Mesti T, Boc M, Rebersek M, Volk N, et al. Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience. Radiol Oncol 2016; 50: 226–31. doi: 10.1515/raon-2015-0030 OcvirkJ MoltaraME MestiT BocM RebersekM VolkN Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience Radiol Oncol 2016 50 226 31 10.1515/raon-2015-0030 Open DOISearch in Google Scholar

17. Saletti P, Molinari F, De Dosso S, Frattini M. EGFR signaling in colorectal cancer: a clinical perspective. Gastrointest Cancer Targets Ther 2015; 5: 21–38. doi: 10.2147/GICTT.S49002 SalettiP MolinariF De DossoS FrattiniM EGFR signaling in colorectal cancer: a clinical perspective Gastrointest Cancer Targets Ther 2015 5 21 38 10.2147/GICTT.S49002 Open DOISearch in Google Scholar

18. Martin J, Petrillo A, Smyth EC, Shaida N, Khwaja S, Cheow H, et al. Colorectal liver metastases: current management and future perspectives. World J Clin Oncol 2020; 11: 761–808. doi: 10.5306/wjco.v11.i10.761 MartinJ PetrilloA SmythEC ShaidaN KhwajaS CheowH Colorectal liver metastases: current management and future perspectives World J Clin Oncol 2020 11 761 808 10.5306/wjco.v11.i10.761 Open DOISearch in Google Scholar

19. Di Noia V, Basso M, Marsico V, Cerchiaro E, Rossi S, D’Argento E, et al. DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer. Future Oncol Lond Engl 2019; 15: 2349–60. doi: 10.2217/fon-2017-0025 Di NoiaV BassoM MarsicoV CerchiaroE RossiS D’ArgentoE DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer Future Oncol Lond Engl 2019 15 2349 60 10.2217/fon-2017-0025 Open DOISearch in Google Scholar

20. Voizard N, Ni T, Kiss A, Pugash R, Raphael MJ, Coburn N, et al. Small particle DEBIRI TACE as salvage therapy in patients with liver dominant colorectal cancer metastasis: retrospective analysis of safety and outcomes. Curr Oncol Tor Ont 2022; 29: 209–20. doi: 10.3390/curroncol29010020 VoizardN NiT KissA PugashR RaphaelMJ CoburnN Small particle DEBIRI TACE as salvage therapy in patients with liver dominant colorectal cancer metastasis: retrospective analysis of safety and outcomes Curr Oncol Tor Ont 2022 29 209 20 10.3390/curroncol29010020 Open DOISearch in Google Scholar

21. Pereira PL, Iezzi R, Manfredi R, Carchesio F, Bánsághi Z, Brountzos E, et al. The CIREL cohort: a prospective controlled registry studying the real-life use of irinotecan-loaded chemoembolisation in colorectal cancer liver metastases: interim analysis. Cardiovasc Intervent Radiol 2021; 44: 50–62. doi: 10.1007/s00270-020-02646-8 PereiraPL IezziR ManfrediR CarchesioF BánsághiZ BrountzosE The CIREL cohort: a prospective controlled registry studying the real-life use of irinotecan-loaded chemoembolisation in colorectal cancer liver metastases: interim analysis Cardiovasc Intervent Radiol 2021 44 50 62 10.1007/s00270-020-02646-8 Open DOISearch in Google Scholar